3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
Social Determinants of Health
2
Electrocardiography
2
Echocardiography
2
zanubrutinib
1
sofosbuvir-velpatasvir drug combination
1
ribociclib
1
palbociclib
1
acalabrutinib
1
abemaciclib
1
Vascular Stiffness
1
Standard of Care
1
Restraint, Physical
1
Referral and Consultation
1
Quality of Life
1
Pulse Wave Analysis
1
Practice Guidelines as Topic
1
Positron-Emission Tomography
1
Physical Conditioning, Human
1
Patient Navigation
1
Nutrition Assessment
1
Methods
1
Magnetic Resonance Spectroscopy
1
Interviews as Topic
1
High-Intensity Interval Training
1
Hematologic Tests
1
Health Information Exchange
1
Geritol
1
Fish Oils
1
Fatty Acids, Omega-3
1
Ethanol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cardiovascular Diseases
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
1 year
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled